← Eichor
Study identifier: NCT06626230 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Safety of Anal Curcumin

Condition: Anal High Grade Squamous Intraepithelial Lesion  ·  Sponsor: Lisa Flowers

PhasePhase 1
Planned participants48
Who can joinAll sexes, 30 Years to no upper limit
Healthy volunteersYes

About this study

The purpose of this study is to see if curcumin can reverse anal high-grade squamous intraepithelial lesions (aHSIL) (high-grade anal precancerous cells or high-grade abnormal cells) in people living with HIV to avoid current treatments such as ablation (destroying abnormal cells with heat or surgical excision (cutting out the abnormal cells)), which have potential short- and long-term side effects.

This description comes directly from the study's public registry record.

Talk to the study team

Lisa Flowers, MD, MPH  ·  404-251-8931  ·  lflowe2@emory.edu

Always discuss trial participation with your own doctor first.

Locations (2)

Grady Memorial HospitalAtlanta, Georgia, United StatesRecruiting
Grady Hospital - Ponce De Leon ClinicAtlanta, Georgia, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06626230